Guo-Ying Liu
Overview
Explore the profile of Guo-Ying Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
He S, Liu G, Yu Y, Wang L, Zhang G, Peng D, et al.
Radiother Oncol
. 2024 Dec;
203():110687.
PMID: 39709030
Background: To evaluate the efficacy of local-regional radiotherapy (LRRT) in de novo metastatic nasopharyngeal carcinoma (dm NPC) patients receiving chemo-immunotherapy as first-line treatment and select the beneficiaries from LRRT. Methods...
2.
He S, Liu G, Yu Y, Wang L, Zhang G, Peng D, et al.
Oral Oncol
. 2024 Oct;
159:107074.
PMID: 39393309
Objectives: This study aims to better manage de novo metastatic nasopharyngeal carcinoma (NPC) patients receiving palliative immuno-chemotherapy (PICT), thereby easily determining individual survival outcomes. Materials And Methods: Patients with de...
3.
Sheng X, Qiu C, Wang L, Du Y, Tang L, Chen J, et al.
Chemistry
. 2024 Aug;
30(63):e202402402.
PMID: 39186035
Efficient transition-metal-free synthesis of benzo[b]azepines and oxindoles is achieved via a radical relay cascade strategy employing halogen atom transfer (XAT) for aryl radical generation followed by intramolecular hydrogen atom transfer...
4.
Liu G, Ye Y, Jiang Y, Chen G, Xia W, Huang Y, et al.
BMJ
. 2024 Jun;
385:e077890.
PMID: 38897625
Objective: To compare the effectiveness and safety of nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) with gemcitabine and cisplatin as an alternative first line treatment option for recurrent or metastatic nasopharyngeal carcinoma....
5.
Liu G, Tang L, Li J, Yang S, Chen M
Chem Commun (Camb)
. 2024 Apr;
60(33):4471-4474.
PMID: 38563905
Herein, a palladium-catalyzed regioselective alkynylation, esterification, and amination of allylic -difluorides C-F bond activation/transmetallation/β-C elimination or nucleophilic attack has been achieved. This innovative protocol showcases an extensive substrate range and...
6.
Du Y, Sheng X, Tang L, Chen J, Liu G, Hu H, et al.
Org Lett
. 2024 Mar;
26(13):2662-2667.
PMID: 38530133
A novel class of alkyne-tethered amides facilitates an unprecedented photoinduced palladium-catalyzed radical relay formal [5 + 2] reaction. This innovative strategy allows for the rapid construction of diverse fused benzoazepine...
7.
Liang H, Jiang Y, Liu G, Wang L, Wang J, Lu N, et al.
Nat Commun
. 2024 Feb;
15(1):1029.
PMID: 38310101
The antiangiogenic agent apatinib has been shown to clinically improve responses to immune checkpoint inhibitors in several cancer types. Patients with N3 nasopharyngeal carcinoma have a high risk of distant...
8.
Tang L, Liu G, Li J, Chen M
Org Lett
. 2023 Dec;
25(50):9064-9069.
PMID: 38091374
Significant advancements in synthesis of monofluoroalkenes via palladium-catalyzed reactions involving allylic -difluorides and diverse nucleophiles have been achieved. This method allows regioselective arylation, alkylation, allylation, alkenylation, and hydrogenation of allylic...
9.
Lu N, Jiang Y, Xia W, Huang Y, Xie C, Xu C, et al.
EClinicalMedicine
. 2023 Aug;
62:102136.
PMID: 37593221
Background: There are limited treatment options for patients with metastatic nasopharyngeal carcinoma (mNPC) after failure of platinum-based chemotherapy. In this trial, we assessed the efficacy and safety of sintilimab plus...
10.
Liu G, Li Z, Chen X, Xia W, Yao H, Xiang Y
Head Neck
. 2023 Aug;
45(10):2571-2579.
PMID: 37554098
Objective: Our objective was to establish a prognostic model for patients with de novo metastatic nasopharyngeal carcinoma (NPC) who received chemotherapy followed by locoregional radiotherapy (LRRT) to identify candidates for...